Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec

This article was originally published in The Pink Sheet Daily

Executive Summary

Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.

You may also be interested in...



Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb

Ranbaxy has acquired the U.S. rights to a group of 13 branded dermatology products from Bristol-Myers Squibb, the Indian firm announced May 28. Bristol retains ex-U.S. rights to the products

Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb

Ranbaxy is looking for more strategic product acquisitions to build its branded division, firm tells “The Pink Sheet” DAILY.

Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb

Ranbaxy is looking for more strategic product acquisitions to build its branded division, firm tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel